Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis

Journal of Cancer

Volumn 5, Issue 6, 2014, Pages 465-471

  Mairinger, Fabian D ^a   Walter, Robert F H ^a   Werner, Robert ^a   Christoph, Daniel C ^a   Ting, Saskia ^a   Vollbrecht, Claudia ^b   Zarogoulidis, Konstantinos ^c   Huang, Haidong ^d   Li, Qiang ^d   Schmid, Kurt W ^a   Wohlschlaeger, Jeremias ^a   Zarogoulidis, Paul ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoid; CRHR2; FIGF; FLT4; HIF1A; KDR; Lung cancer

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; FOS INDUCED GROWTH FACTOR; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ANGIOGENESIS; ARTICLE; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; MALE; METASTASIS; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RNA EXTRACTION; TUMOR GROWTH; TUMOR INVASION; TUMOR VASCULARIZATION;

EID: 84902521061     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.9235     Document Type: Article

References (48)

1. Eramo A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ, 2008; 15(3): 504-14.
2. Jett J.R. and Midthun D.E. Screening for lung cancer: current status and future directions: Thomas A. Neff lecture. Chest, 2004. 125(5 Suppl): 158-62.
3. Mallick R., et al. MicroRNAs and lung cancer: Biology and applications in diagnosis and prognosis. J Carcinog, 2010; 9.
4. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med, 2010; 134(11): 1628-38.
5. Takei H., et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg, 2002; 124(2): 285-92.
6. Swarts D.R., et al. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta, 2012; 1826(2): 255-71.
7. Thomas C.FJr., et al. Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement. Chest, 2001. 119(4): 1143-50.
8. Travis W.D., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol, 1998; 22(8): 934-44.
9. Asamura H., et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol, 2006. 24(1): 70-6.
10. Cardillo G., et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg, 2004. 77(5): 1781-5.
11. Beasley M.B., et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol, 2000. 31(10): 1255-65.
12. Fink G., et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest, 2001. 119(6): 1647-51.
13. Garcia-Yuste M., et al. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg, 2007. 31(2): 192-7.
14. Pelosi G, et al. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. Cancer, 2005. 103(6): 1154-64.
15. Rea F, et al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardiothorac Surg, 2007. 31(2): 186-91.
16. Travis WD. Lung tumours with neuroendocrine differentiation. Eur J Cancer, 2009. 45( Suppl 1): 251-66.
17. Scott WJ. Surgical treatment of other bronchial tumors. Chest Surg Clin N Am, 2003; 13(1): 111-28.
18. Travis WD, et al. Pathology and genetics of tumours of the lung, pleura, thymus and heart; World Health Organization classification of tumours. Lyon Oxford: IARC Press. 2004: 344.
19. Jagoe R., et al. Observer variation in quantification of immunocytochemistry by image analysis. Histochem J, 1991; 23(11-12): 541-7.
20. Jarlov AE. Observer variation in the diagnosis of thyroid disorders. Criteria for and impact on diagnostic decision-making. Dan Med Bull, 2000. 47(5): 328-39.
21. Travis W.D., et al. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol, 1998; 29(3): 272-9.
22. den Bakker MA, et al. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability. Histopathology, 2010; 56(3): 356-63.
23. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971; 285(21): 1182-6.
24. Kim JW, et al. Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. Cancer Res Treat, 2013; 45(4): 325-33.
25. Yip C, et al. Imaging assessment of lung tumor angiogenesis: insights and innovations. Semin Respir Crit Care Med, 2014; 35(1): 112-28.
26. Ullah E, Nagi AH, Ashraf M. Angiogenesis and mast cell density as predictors of patient survival in squamous cell carcinoma of lung. J Cancer Res Ther, 2013; 9(4): 701-5.
27. Liu B, et al. Polymorphisms of HIF1A gene are associated with prognosis of early stage non-small-cell lung cancer patients after surgery. Med Oncol, 2014; 31(4): 877.
28. Subtil FS, et al. Carbon ion radiotherapy of human lung cancer attenuates HIF-1 signaling and acts with considerably enhanced therapeutic efficiency. FASEB J, 2014; 28(3): 1412-21.
29. Crino L, Metro G. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev, 2014; 23(131): 79-91.
30. Natale RB, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol, 2011; 29(8): 1059-66.
31. Scagliotti GV, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol, 2012; 30(17): 2070-8.
32. Herbst RS, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet, 2011; 377(9780): 1846-54.
33. Scagliotti G, Govindan R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist, 2010; 15(5): 436-46.
34. Kutluk CB, et al. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther, 2013; 12(6): 992-1001.
35. Reck M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol, 2014; 15(2): 143-55.
36. Ren J, et al. Cationic Liposome Mediated Delivery of FUS1 and hIL-12 Coexpression Plasmid Demonstrates Enhanced Activity against Human Lung Cancer. Curr Cancer Drug Targets, 2014.
37. Cheng X, et al. Tumor-Specific Delivery of Histidine-Rich Glycoprotein Suppresses Tumor Growth and Metastasis by Anti-Angiogenesis and Vessel Normalization. Curr Gene Ther, 2014.
38. Lai WY, et al. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. Biomaterials, 2014; 35(9): 2905-14.
39. Xu JY, et al. Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration. Mol Clin Oncol, 2013; 1(2): 331-336.
40. Shuman MLA, et al. Dietary intake of a plant phospholipid/lipid conjugate reduces lung cancer growth and tumor angiogenesis. Carcinogenesis, 2014.
41. Kachroo P, et al. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res, 2013; 32(1): 97.
42. Song JM, et al. Dimethylaminoparthenolide, a water soluble parthenolide, suppresses lung tumorigenesis through down-regulating the STAT3 signaling pathway. Curr Cancer Drug Targets, 2014; 14(1): 59-69.
43. Sang CY, et al. DPMA, a deoxypodophyllotoxin derivative, induces apoptosis and anti-angiogenesis in non-small cell lung cancer A549 cells. Bioorg Med Chem Lett, 2013; 23(24): 6650-5.
44. Zarogoulidis P, Yarmus L, and Zarogoulidis K. New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer. Ther Deliv, 2013. 4(10): 1221-3.
45. Dorff TB, et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res, 2010. 16(11): 3028-34.
46. Hohenforst-Schmidt W, et al. Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies. Drug Des Devel Ther, 2013; 7: 571-83.
47. Baliaka A., et al. Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-diethylaminoethyl-dextran methyl methacrylate copolymer non-viral vector-p53. Gene Ther, 2014; 21(2): 158-67.
48. Zarogoulidis P, et al. Interleukin-6 cytokine: a multifunctional glycoprotein for cancer. Immunome Res, 2013; 9(62): 16535.